RxDoctor Payments DataLook up a doctor →

Rafiq Ramadan, MD

Interventional Cardiology · Saint Louis, MONPI 1396769055

Payments from drug & device makers

$156,817in general payments, 2019–2025

Across 1,240 payments — averaging $126.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$68K
  • Impulse Dynamics (USA) Inc.$54K
  • Boston Scientific$23K
  • Novartis$2K
  • Medtronic$985
  • Boehringer Ingelheim$952
  • plus $7K from 41 others

What the payments were for

  • Consulting fees$7,20034%
  • Travel & lodging$1,4597%
  • Food & beverage$12,56859%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$156,817 in reported general payments places this provider in the 80th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$273,058
Medicare patients
512
Services billed
4,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$271,204
XareltoRivaroxaban66$84,277
EntrestoSacubitril/Valsartan69$80,229
OzempicSemaglutide34$52,819
JardianceEmpagliflozin38$47,761
Repatha SureclickEvolocumab45$42,859
BrilintaTicagrelor45$28,446
TrulicityDulaglutide19$18,948
FarxigaDapagliflozin Propanediol16$14,143
Dofetilide39$12,331
Ranolazine ErRanolazine28$2,593
Nebivolol Hcl22$2,200
Potassium Chloride30$1,825
Nifedipine ErNifedipine48$1,725
Carvedilol202$1,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$606$271,204238 claims
Johnson & JohnsonXarelto$641$84,27766 claims
NovartisEntresto$2,076$80,22969 claims
Novo NordiskOzempic$108$52,81934 claims
Boehringer IngelheimJardiance$952$47,76138 claims
AstraZenecaBrilinta, Farxiga$590$42,58961 claims
Lilly USA, LLCTrulicity$128$18,94819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →